RA Capital Healthcare Fund LP 4
4 · Acrivon Therapeutics, Inc. · Filed Jun 22, 2026
Research Summary
AI-generated summary of this filing
Acrivon (ACRV) RA Capital Receives 20,275-Share Option Grant
What Happened
RA Capital Management, L.P. (a >10% holder) was granted an option covering 20,275 shares of Acrivon Therapeutics (ACRV) on 2026-06-17. The award shows an exercise price of $0.00 and a reported acquisition value of $0.00 (derivative award). The option vests subject to continuous service and other conditions described in the filing.
Key Details
- Transaction date: 2026-06-17; Form 4 filed 2026-06-22 (appears later than the typical 2-business-day Form 4 filing window).
- Transaction type/code: A (grant/award of a derivative option).
- Shares/options involved: option for 20,275 shares; exercise price reported $0.00; reported dollar value $0.00.
- Shares owned after transaction: not specified in the provided summary.
- Notable footnotes:
- Vesting occurs the day before the issuer’s next annual meeting, subject to Dr. Derek DiRocco’s continuous service.
- RA Capital acts as investment adviser to funds (RA Capital Healthcare Fund and RA Capital Nexus Fund II) and disclaims beneficial ownership except for pecuniary interest.
- Dr. Derek DiRocco holds the option for the benefit of those funds and must remit any net cash or stock received on exercise to the adviser to offset advisory fees; the reporting parties disclaim beneficial ownership.
- Remark: Dr. Derek DiRocco is a partner at the adviser and serves on Acrivon’s board.
Context
This was a derivative award (option grant), not an open-market buy or sale — it does not by itself indicate a purchase or immediate sale of shares. The option is held for the benefit of institutional funds rather than as a personal holding of the adviser’s partners; reported mechanics indicate any proceeds would offset fees rather than remain with Dr. DiRocco. Institutional filings by investment managers (10% owners) often reflect fund arrangements and compensation structures rather than direct insider sentiment.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1][F2][F3]2026-06-17+20,275→ 20,275 total(indirect: See Footnotes)Exercise: $1.52Exp: 2036-06-16→ Common Stock (20,275 underlying)
Footnotes (3)
- [F1]The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to Dr. Derek DiRocco's continuous service through the applicable vesting date.
- [F2]RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
- [F3]Under Dr. DiRocco's arrangement with the Adviser, Dr. DiRocco holds the option for the benefit of the Fund and the Nexus Fund II. Dr. DiRocco is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.